Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial

被引:48
作者
Gault, Emma Jane [1 ]
Perry, Rebecca J. [1 ]
Cole, Tim J. [2 ]
Casey, Sarah [3 ]
Paterson, Wendy F. [1 ]
Hindmarsh, Peter C. [4 ]
Betts, Peter [5 ]
Dunger, David B. [6 ]
Donaldson, Malcolm D. C. [1 ]
机构
[1] Univ Glasgow, Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland
[2] UCL Inst Child Hlth, MRC Ctr Epidemiol Child Hlth, London, England
[3] Royal Hosp Sick Children, Dept Clin Trials, Dept Pharm, Glasgow G3 8SJ, Lanark, Scotland
[4] UCL Inst Child Hlth, Clin & Mol Genet Unit, London, England
[5] Southampton Univ Hosp NHS Trust, Dept Paediat, Southampton, Hants, England
[6] Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2011年 / 342卷
关键词
GROWTH-HORMONE TREATMENT; ESTROGEN REPLACEMENT; GIRLS; THERAPY; MULTICENTER; NORMALIZATION; MANAGEMENT; STATURE; AGE;
D O I
10.1136/bmj.d1980
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To examine the effect of oxandrolone and the timing of pubertal induction on final height in girls with Turner's syndrome receiving a standard dose of growth hormone. Design Randomised, double blind, placebo controlled trial. Setting 36 paediatric endocrinology departments in UK hospitals. Participants Girls with Turner's syndrome aged 7-13 years at recruitment, receiving recombinant growth hormone therapy (10 mg/m(2)/week). Interventions Participants were randomised to oxandrolone (0.05 mg/kg/day, maximum 2.5 mg/day) or placebo from 9 years of age. Those with evidence of ovarian failure at 12 years were further randomised to oral ethinylestradiol (year 1, 2 mu g daily; year 2, 4 mu g daily; year 3, 4 months each of 6, 8, and 10 mu g daily) or placebo; participants who received placebo and those recruited after the age of 12.25 years started ethinylestradiol at age 14. Main outcome measure Final height. Results 106 participants were recruited, of whom 14 withdrew and 82/92 reached final height. Both oxandrolone and late pubertal induction increased final height: by 4.6 (95% confidence interval 1.9 to 7.2) cm (P=0.001, n=82) for oxandrolone and 3.8 (0.0 to 7.5) cm (P=0.05, n=48) for late pubertal induction with ethinylestradiol. In the 48 children who were randomised twice, the effects on final height (compared with placebo and early induction of puberty) of oxandrolone alone, late induction alone, and oxandrolone plus late induction were similar, averaging 7.1 (3.4 to 10.8) cm (P<0.001). No cases of virilisation were reported. Conclusion Oxandrolone had a positive effect on final height in girls with Turner's syndrome treated with growth hormone, as did late pubertal induction with ethinylestradiol at age 14 years. However, these effects were not additive, so using both had no advantage. Oxandrolone could, therefore, be offered as an alternative to late pubertal induction for increasing final height in Turner's syndrome.
引用
收藏
页数:9
相关论文
共 36 条
  • [1] [Anonymous], 1983, ASSESSMENT SKELETAL
  • [2] Puberty induction in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels
    Bannink, E. M. N.
    van Sassen, C.
    van Buuren, S.
    de Jong, F. H.
    Lequin, M.
    Mulder, P. G. H.
    Keizer-Schrama, S. M. P. F. de Muinck
    [J]. CLINICAL ENDOCRINOLOGY, 2009, 70 (02) : 265 - 273
  • [3] Recombinant growth hormone for children and adolescents with Turner syndrome
    Baxter, L.
    Bryant, J.
    Cave, C. B.
    Milne, R.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (01):
  • [4] Phenotype, ovarian function, and growth in patients with 45,X/47,XXX Turner mosaicism: Implications for prenatal counseling and estrogen therapy at puberty
    Blair, J
    Tolmie, J
    Hollman, AS
    Donaldson, MDC
    [J]. JOURNAL OF PEDIATRICS, 2001, 139 (05) : 724 - 728
  • [5] Final height of patients with Turner's syndrome treated with growth hormone (GH): Indications for GH therapy alone at high doses and late estrogen therapy
    Cacciari, E
    Mazzanti, L
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (12) : 4510 - 4515
  • [6] Near normalization of final height with adapted doses of growth hormone in Turner's syndrome
    Carel, JC
    Mathivon, L
    Gendrel, C
    Ducret, JP
    Chaussain, JL
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (05) : 1462 - 1466
  • [7] Self-esteem and social adjustment in young women with Turner syndrome -: Influence of pubertal management and sexuality:: Population-based cohort study
    Carel, Jean-Claude
    Elie, Caroline
    Ecosse, Emmanuel
    Tauber, Maithe
    Leger, Juliane
    Cabrol, Sylvie
    Nicolino, Marc
    Brauner, Raja
    Chaussain, Jean-Louis
    Coste, Joel
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (08) : 2972 - 2979
  • [8] Growth hormone therapy of Turner syndrome: The impact of age of estrogen replacement on final height
    Chernausek, SD
    Attie, KM
    Cara, JF
    Rosenfeld, RG
    Frane, J
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (07) : 2439 - 2445
  • [9] Role of oestrogen therapy in the management of short stature in Turner syndrome
    Chernausek, SD
    Attie, KM
    [J]. ACTA PAEDIATRICA, 1999, 88 : 130 - 132
  • [10] SITAR-a useful instrument for growth curve analysis
    Cole, Tim J.
    Donaldson, Malcolm D. C.
    Ben-Shlomo, Yoav
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2010, 39 (06) : 1558 - 1566